Experiments on risk framing and moral appeal in the context of the Coronavirus spread

Last registered on December 07, 2021

Pre-Trial

Trial Information

General Information

Title
Experiments on risk framing and moral appeal in the context of the Coronavirus spread
RCT ID
AEARCTR-0005573
Initial registration date
March 19, 2020
Last updated
December 07, 2021, 3:21 AM EST

Locations

Region

Primary Investigator

Affiliation
University of Hamburg

Other Primary Investigator(s)

PI Affiliation
University of Leipzig and idiv
PI Affiliation
University of Leipzig and idiv
PI Affiliation
University of Hamburg

Additional Trial Information

Status
On going
Start date
2020-03-19
End date
2022-12-31
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
We aim at a better understanding of what shapes individual behavior in times of the spread of the Coronavirus.
External Link(s)

Registration Citation

Citation
Bos, Björn et al. 2021. "Experiments on risk framing and moral appeal in the context of the Coronavirus spread." AEA RCT Registry. December 07. https://doi.org/10.1257/rct.5573-1.5000000000000002
Experimental Details

Interventions

Intervention(s)
Our study exploits the spread of the Coronavirus in Germany.
Intervention Start Date
2020-03-19
Intervention End Date
2022-12-31

Primary Outcomes

Primary Outcomes (end points)
- private provision of a public good (e.g., “social distancing”, hygiene measures, and willingness to get tested)
- motivation to provide the public good
- support of enforcement of the public good provision
- risk taking
- truth-telling
- infection with the Coronavirus
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
We conduct a panel survey experiment with 3 waves. The survey includes questions on subjects’ current health level, past and planned behavior related to the Coronavirus, support for governmental measures to slow the Coronavirus, as well as stated preferences. Please refer to our Pre-Analysis Plan for more details.
Experimental Design Details
Not available
Randomization Method
Randomization of respondents over treatment groups in the survey is done via a computer and independent for each information treatment.
Randomization Unit
Individual randomization over survey respondents.
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
The first survey wave will encompass 3.650 respondents. Depending on the willingness to participate in the survey again (and the timing of survey waves two and three), approximately 2.660 respondents will be in the second survey wave and approximately 1.330 respondents will be in the third survey wave.
Sample size: planned number of observations
The first survey wave will encompass 3.650 respondents. Depending on the willingness to participate in the survey again (and the timing of survey waves two and three), approximately 2.660 respondents will be in the second survey wave and approximately 1.330 respondents will be in the third survey wave.
Sample size (or number of clusters) by treatment arms
For each of the two information treatments, we assign subjects with an equal probability into the respective control and treatment groups. Hence, we expect 1/3 of all subjects in the respective control group, 1/3 of the subjects in the first respective treatment group, and 1/3 of all subjects in the second respective treatment group.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
IRB

Institutional Review Boards (IRBs)

IRB Name
WiSo Laboratories Hamburg
IRB Approval Date
2020-03-18
IRB Approval Number
N/A
Analysis Plan

There are documents in this trial unavailable to the public. Use the button below to request access to this information.

Request Information